Not exact matches
Our job now is to figure out how to
make immunotherapy effective against those tumors with
small numbers of
mutations.
Only a
small group of highly skilled virologists could
make use of the
mutations, he says, and the well - known passaging method is «not an «Aha» idea.»
It's the more common genetic
mutations that have a
smaller effect that are
making it through the genetic gauntlet.
20 - 30 % of patients with acute myeloid leukemia have
mutations of the FLT3 biomarker that
make them eligible for several FLT3 - targeted
small molecule therapies currently in late stage clinical trials.
In addition to the large CNV
mutations they had spotted earlier, they also found de novo changes in single base pairs of DNA — known as single - nucleotide variants (SNVs)-- and
small de novo insertions or deletions in chromosomes, all of which
made the picture even more complex.